Program Chairs: Robert Orlowski, MD, PhD; Jatin J. Shah, MD; Edward A. Stadtmauer, MD; Nikhil C. Munshi, MD; Kenneth C. Anderson, MD

Thursday, May 4, 2017
6:00PM – 9:00PM  | Registration and Welcome Reception

Friday, May 5, 2017
7:00AM  | Breakfast
8:00  | Introduction
Jatin J. Shah, MD; Edward A. Stadtmauer, MD
8:10  | Plenary Talk
Carl H. June, MD

Session 1: Cellular Therapy
Chair: Edward A. Stadtmauer, MD

9:00  | Anti-CS-1 CAR T-Cells for Myeloma
Maung Myo Htut, MD
9:20  | Targeting BCMA with CAR
Adam D. Cohen, MD
9:40  | Poseida BCMA CARtyrin
Devon J. Shedlock
10:00  | Break
10:20  | Designing CAR T-Cells and Targets
Michael C. Milone, MD, PhD
10:40  | Allogenic CAR T-Cell Development Targeting CS1
Roman Galetto, PhD
11:00  | Anti-CD19 CAR T-Cells for Multiple Myeloma
Alfred L. Garfall, MD
11:20  | Biomarkers of Response and Toxicity in CAR-T Cell Trial
Jan Joseph Melenhorst, PhD
11:40  | Managing CAR Toxicity: MDACC Experience
Sattva S. Neelapu, MD
12:00 PM  | Managing CAR Toxicity: UPenn Experience
David L. Porter, MD
12:20  | Lunch
Afternoon Plenary
1:00 | Leveraging Innate Immune System
Madhav V. Dhodapkar, MD

Session 2: Monoclonal Antibodies
Chairs: Sergio A. Giralt, MD; Robert Orlowski, MD

1:40 | Certain KIR-HLA Genotypes Show Improved Progression-Free Survival in Patients with Myeloma Treated with Isatuximab (SAR650984, anti-CD38 mAb), Lenalidomide and Dexamethasone
Rajalingam Raja, PhD

2:00 | The Challenge of NK-Depletion by Daratumumab and Strategies to Overcome
Jinhua Yu, PhD

2:20 | Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance Through CD38 Internalization
Flavia Pichiorri, PhD

2:40 | Immunomodulatory Regulation of CD38
Yu-Tzu Tai, PhD

3:00 | Defining Absopal Effects in Myeloma
Alexander M. Lesokhin, MD

3:20 | Break

Session 3: Vaccine Therapy
Chair: David E. Avigan, MD

3:40 | Dendritic Cell-Based Vaccine
Jaclayn Rosenblatt, MD

4:00 | WT1 Heteroclitic Epitope Immunization Following Autologous Stem Cell Transplantation
Guenther Koehne, MD, PhD

4:20 | Vaccine Study Combinations and Checkpoint
David J. Chung, MD, PhD

4:40 | Combination Immunotherapy Approach to Treat Myeloma and Beyond: Bench top Discovery to Clinical Application
Jooeun Bae, PhD

6:00 PM – 10:00 PM | Reception
Museum of American History
Saturday, May 6, 2017

7:00  Breakfast

Session 4: Novel Therapies/Targets
Chair: Sundar Jagannath, MD

8:00  Clinical Perspective and Practical Implications Recap from Day One
      Jatin J. Shah, MD

8:20  Targeting CD46
      Daniel Sherbenou, MD, PhD

8:40  TBD
      Paul R. Eisenberg

9:00  NEO-D in Amyloid
      Brandon M. Weiss, MD

9:15  11-14F
      Suzanne Lentzsch, MD, PhD

9:30  The Role of Serum BCMA in Monitoring, Predicting Outcomes and Immune Deficiency of Multiple Myeloma
      James R. Berenson, MD

9:45  BCMA-Bite
      Adam D. Cohen, MD

10:00 Break

Session 5: Checkpoints and Mab
Chair: Enrique M. Ocio, MD, PhD; Patricia Maiso, PhD

10:20  T-Cell Fate in Myeloma at Diagnosis and After IMiD-Based Treatment
      David S. Ritchie, MBBS, PhD

10:40  Elotuzumab Maintenance Therapy
      Hearn J. Cho, MD, PhD

11:00  Counteracting PD-L1/PD-L2 Immune Suppression in Multiple Myeloma through Kinase Inhibition
      James Driscoll, MD, PhD

11:20  BCMA-ADC
      PK Morrow, MD

11:40  Novel HDAC 6 Inhibitor ACY-241 with Anti-PD-L1 Antibody
      Arghya Ray, PhD

12:00 PM  NYSEO-1 TCR and CRISPER in Myeloma
      Yangbing Zhao, MD, PhD
12:20 | The Enhancement of Anti-Tumor Activities of Slinexor When Combined With Immune Checkpoint Inhibitors
     | Trinayan Kashyap, MS
12:40 | SGN-CD48A
     | Abraham P. Fong, MD, PHD
1:00  | Concluding Remarks
     | Jatin J. Shah, MD; Edward A. Stadtmauer, MD
1:10 PM | Lunch